High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Date: Thursday, November 12, 2020
Time: 8:00am PDT / 11:00am EDT
Duration: 45 minutes

Drug-induced QT interval prolongation and Torsades de Pointes (TdP) arrhythmias are the leading causes for compound attrition during drug development. To assess potential cardiotoxicity of compounds, the Comprehensive in vitro Proarrhythmia Assay (CiPA) is a cardiac safety testing paradigm that includes in vitro assays using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). To adopt the CiPA paradigm, Eurofins Discovery developed a high-throughput hiPSC-CM assay using calcium-sensitive dyes detected by high-speed imaging platform, the FLIPR® Penta. This assay can provide an in vitro drug-induced proarrhythmia assessment and strengthen pharmacological safety profiles of drug candidates.


Panida Lertkiatmongkol, PhD
Senior Scientist and Group Leader
Cell-based screening, Eurofins DiscoverX